◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › R › RARE

Ultragenyx (RARE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-30

Ultragenyx (RARE) operates in the BIOTECHNOLOGY industry and is headquartered in Novato, United States with about 1,371 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, RARE reported $673M in revenue and ($575M) in net income.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

Interactive charts & full statements → Open the RARE valuation workbench →

RARE Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$717M	$673M	$560M	$434M	$363M	$351M	$271M	$104M	$51M	$3M	$0M	$0M	$0M	—	—	—
Gross Profit	$596M	$564M	$484M	$389M	$335M	$335M	$265M	$95M	$50M	$3M	$0M	($1M)	$0M	—	—	—
Gross Margin %	83.1%	83.8%	86.3%	89.6%	92.2%	95.4%	97.7%	91.3%	97.8%	100.0%	100.0%	—	—	—	—	—
Operating Income (EBIT)	($529M)	($535M)	($536M)	($569M)	($649M)	($382M)	($330M)	($424M)	($371M)	($329M)	($248M)	($148M)	($57M)	($32M)	($16M)	($7M)
Operating Margin %	-73.8%	-79.5%	-95.7%	-131.1%	-178.6%	-108.6%	-121.8%	-409.0%	-721.2%	-12593.5%	-186471.4%	—	—	—	—	—
Net Income	($586M)	($575M)	($569M)	($607M)	($707M)	($454M)	($187M)	($403M)	($198M)	($302M)	($246M)	($146M)	($60M)	($35M)	($16M)	($7M)
Net Margin %	-81.8%	-85.4%	-101.6%	-139.7%	-194.7%	-129.2%	-68.8%	-388.3%	-383.8%	-11567.3%	-184867.7%	—	—	—	—	—
EBITDA	($473M)	($474M)	($469M)	($516M)	($640M)	($410M)	($140M)	($390M)	($178M)	($323M)	($245M)	($146M)	($56M)	($35M)	($16M)	($7M)
Earnings Per Share (EPS)	$-5.84	$-5.83	$-6.29	$-8.25	$-10.12	$-6.70	$-3.07	$-7.12	$-3.97	$-7.12	$-6.21	$-3.96	$-2.08	$-1.21	$-0.71	$-0.30
Shares Outstanding (M)	102M	99M	91M	74M	70M	68M	61M	57M	50M	42M	40M	37M	29M	29M	23M	23M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RARE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$214M	$136M	$207M	$160M	$166M	$139M	$165M	$139M
Gross Profit	$180M	$106M	$178M	$132M	$143M	$111M	$148M	$118M
Gross Margin %	84.1%	77.9%	86.0%	82.5%	86.2%	79.4%	89.8%	84.9%
Operating Income (EBIT)	($75M)	($169M)	($114M)	($171M)	($108M)	($143M)	($122M)	($132M)
Operating Margin %	-35.0%	-124.3%	-55.1%	-106.8%	-64.8%	-102.6%	-74.2%	-94.6%
Net Income	($92M)	($185M)	($129M)	($180M)	($115M)	($151M)	($133M)	($134M)
Net Margin %	-43.0%	-136.0%	-62.3%	-112.8%	-69.0%	-108.5%	-80.9%	-95.7%
EBITDA	($61M)	($155M)	($100M)	($157M)	($91M)	($126M)	($109M)	($109M)
Earnings Per Share (EPS)	$-0.90	$-1.84	$-1.29	$-1.81	$-1.17	$-1.57	$-1.39	$-1.40
Shares Outstanding (M)	102M	101M	100M	100M	98M	96M	96M	95M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RARE Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($485M)	($466M)	($414M)	($475M)	($380M)	($339M)	($132M)	($345M)	($291M)	($254M)	($161M)	($106M)	($45M)	($31M)	($13M)	($6M)
Capital Expenditures (CapEx)	$4M	$6M	$7M	$47M	$146M	$73M	$44M	$25M	$4M	$3M	$10M	$5M	$2M	$0M	$1M	$1M
Free Cash Flow (FCF)	($489M)	($472M)	($422M)	($522M)	($527M)	($412M)	($176M)	($370M)	($295M)	($257M)	($171M)	($111M)	($47M)	($32M)	($14M)	($6M)
FCF Margin %	-68.3%	-70.1%	-75.3%	-120.1%	-144.9%	-117.2%	-65.0%	-357.0%	-572.2%	-9825.3%	-128694.0%	—	—	—	—	—
Dividends Paid	—	—	—	—	—	—	—	—	—	$0M	$0M	$0M	$4M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RARE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($97M)	($197M)	($100M)	($91M)	($108M)	($166M)	($80M)	($67M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$1M	$13M	$16M	$1M	$2M
Free Cash Flow (FCF)	($98M)	($198M)	($101M)	($93M)	($121M)	($183M)	($80M)	($69M)
FCF Margin %	-45.8%	-145.6%	-48.7%	-58.0%	-72.6%	-131.2%	-48.6%	-49.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RARE Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$1.3B	$1.5B	$1.5B	$1.5B	$1.5B	$1.5B	$1.8B	$1.1B	$720M	$491M	$541M	$560M	$198M	$60M	$88M	$12M
Cash & Cash Equivalents	$125M	$434M	$174M	$214M	$133M	$308M	$714M	$434M	$113M	$100M	$161M	$94M	$24M	$7M	$86M	$11M
Total Liabilities	$1.5B	$1.6B	$1.2B	$1.2B	$1.2B	$600M	$605M	$482M	$111M	$107M	$67M	$28M	$13M	$10M	$4M	$1M
Total Debt (Short + Long-Term)	$76M	$81M	$10M	$13M	$12M	$11M	$9M	$7M	$0M	$0M	$0M	$0M	$0M	$3M	$1M	$0M
Total Shareholders' Equity	($291M)	($80M)	$255M	$275M	$352M	$923M	$1.2B	$654M	$609M	$383M	$474M	$531M	$185M	$50M	$84M	$11M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RARE viewer.

Other Companies in BIOTECHNOLOGY

KARD · Kardigan, Inc. Common Stock — $2 billion
INVA · Innoviva Inc — $2 billion
BCAX · Bicara Therapeutics Inc. Common Stock — $1 billion
LTGO · Latigo Biotherapeutics, Inc. Common Stock — $1 billion
AVBP · ArriVent BioPharma, Inc. Common Stock — $1 billion
DRTS · Alpha Tau Medical Ltd — $1 billion
AVLN · Avalyn Pharma Inc. Common Stock — $1 billion
DMRA · Damora Therapeutics, Inc. — $1 billion

← RAPP All “R” companies RAT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.